首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma.

Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Lorena,Heinst

第一单位： Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.

作者： Lorena,Heinst ^[1] ; Kwang Seok,Lee ^[2] ; Ruth,Berthold ^[1] ; Ilka,Isfort ^[1] ; Svenja,Wosnig ^[1] ; Anna,Kuntze ^[1] ; Susanne,Hafner ^[3] ; Bianca,Altvater ^[4] ; Claudia,Rossig ^[5] ; Pierre,Åman ^[6] ; Eva,Wardelmann ^[1] ; Claudia,Scholl ^[7] ; Wolfgang,Hartmann ^[1] ; Stefan,Fröhling ^[8] ; Marcel,Trautmann ^[1]

作者单位： Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany. ^[1] Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[2] Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Hospital, Ulm, Germany. ^[3] Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany. ^[4] Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.;Cells in Motion Cluster of Excellence, University of Münster, Münster, Germany. ^[5] Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ^[6] Division of Applied Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.;National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany. ^[7] Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.;German Cancer Consortium (DKTK), Heidelberg, Germany.;Institute of Human Genetics, Heidelberg University, Heidelberg, Germany. ^[8]